iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

USFDA concludes Zydus Lifesciences’ Ahmedabad facility inspection with ‘no observations’

10 Jul 2023 , 02:44 PM

Zydus Lifesciences Limited informed that from July 2 to 7, 2023, a USFDA team inspected company’s manufacturing facility at SEZ-2 in Pharmez. The said pre-approval inspection (PAI) ended with no observations.

The USFDA granted final approval to the company on July 4 for Oxcarbazepine Tablets USP, 150 mg, 300 mg, and 600 mg. To treat seizure disorders (epilepsy), oxcarbazepine can be used alone or in combination with other medications.

The product will be developed at the group’s Baddi facility in Himachal Pradesh.

On July 3, the company received the USFDA’s Establishment Inspection Report (EIR) for the inspection conducted at its Pharmez facility from March 20 to 24, 2023. Voluntary Action Indicated (VAI) has been assigned to the said inspection upon completion, according to the EIR report.

At around 2.37 PM, Zydus Lifesciences was trading marginally higher at Rs 582.35, against the previous close of Rs 582.25 on NSE. The counter touched an intraday high and low of Rs 588.10 and Rs 580.10, respectively.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • USFDA
  • Zydus Lifesciences
  • Zydus Lifesciences news
  • Zydus Lifesciences Updates
  • Zydus Lifesciences USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.